Journal publishes paper highlighting Vitamin K2 role in bone and vasculature,
completed as part of Norwegian Research Council grant
Oslo, Norway and Edison, NJ (5 FEB 2019) - Frontiers in Cardiovascular Medicine
has published a new review paper examining calcium supplementation's impact on
bone and cardiovascular health, and the role Vitamin K2 plays in proper calcium
utilization. The review paper is the result of a grant from the Norwegian
Research Council awarded to NattoPharma to fund a 4-year PhD project to document
the effect of calcium metabolism in the body based on the presence or absence of
vitamin K2, MK-7, where NattoPharma has provided MenaQ7® Vitamin K2 as MK-7 for
research conducted at the University of Maastricht, led by Professor Leon
According to the authors, the paper "The bone-vasculature axis: calcium
supplementation and the role of vitamin K", provides an update on current
literature on calcium supplementation among post-menopausal women and chronic
kidney disease (CKD) patients and discusses underlying molecular mechanisms of
vascular calcification. Prof. Schurgers states that therapeutic strategies with
vitamin K2 treatment should be considered to prevent or hold progression of
vascular calcification as a consequence of excessive calcium intake.
"The work conducted in collaboration with NattoPharma under the Norwegian
Research Council grant will provide further evidence that calcium without
adequate vitamin K2 consumption might end up in the soft tissues where it is not
wanted, rather than in the bone matrix, where it is needed," says Prof.
Schurgers, Professor of Biochemistry of Vascular Calcification and Vice Chair of
Biochemistry at the Cardiovascular Research Institute Maastricht (CARIM),
Maastricht University; and senior author and leader of the research project. "In
a recent study by Bolland et al., it was shown that calcium supplementation of
postmenopausal women was associated with a beneficial effect on bone, but also
with increased myocardial infarction, suggesting detrimental effects on the
vascular system possibly by inducing increased vascular calcification. As
calcium supplementation is needed for bone, the precipitation in the vessel wall
needs to be inhibited."
The paper is significant because it adds to the growing body of evidence
substantiating MenaQ7® Vitamin K2 as a bone- and cardiovascular-support
nutrient, according to NattoPharma Chief Medical Officer Dr. Hogne Vik.
"Compromised bone and heart health are not merely age-related issues; rather,
they are signs of a core nutrient deficiency: vitamin K2," says Vik.
"NattoPharma has driven the research confirming vitamin K2's important health
benefits, showing in human studies with healthy participants that the
progression of hardening of the arteries can be halted and even regressed, and
that bone strength can be improved with daily supplementation of MenaQ7 Vitamin
"We are proud that our partnership with Maastricht University and this
prestigious grant have given us an opportunity to further the understanding of
the necessity of obtaining adequate vitamin K2 for human health," Dr. Vik adds.
"We hope these findings will earn the attention of manufacturers and consumers
alike, helping them to recognize that all calcium supplementation must be paired
with vitamin K2 so bone and heart health can be simultaneously supported."
* Prof. Schurgers' research is additionally funded in part via the European
Union's Horizon 2020 research and innovation programme under the Marie
Sklodowska-Curie grant agreement No. 722609 in which NattoPharma is partner.
Wasilewski GB, Vervloet MG, Schurgers LJ. The Bone-Vasculature Axis: Calcium
Supplementation and the Role of Vitamin K. Front. Cardiovasc. Med, 5 Feb 2019.
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the supplement industry world leader in
vitamin K2 research and development. NattoPharma is the exclusive international
supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as
menaquinone-7 (MK-7) with guaranteed actives and stability, clinical
substantiation, and international patents granted and pending; and now the new
MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has
a multi-year research and development program to substantiate and discover the
health benefits of Vitamin K2 for applications in the marketplace for functional
food and dietary supplements, in addition to exclusive access to the research
efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of
the pharmaceutical domain. With a global presence, the company established its
North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma
R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or
For more information, please contact:
Kate Quackenbush, NattoPharma Director of Communications
P: 609-643-0749 x 220; E: kate.quackenbush@nattopharma